Analyst Price Target is $9.00
▲ +324.53% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for TC Biopharm in the last 3 months. The average price target is $9.00, with a high forecast of $9.00 and a low forecast of $9.00. The average price target represents a 324.53% upside from the last price of $2.12.
Current Consensus is
The current consensus among 1 polled investment analysts is to buy stock in TC Biopharm.
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.